Eversana Intouch
NOVEMBER 9, 2023
Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. By 2018, that share had fallen by about half. Meanwhile, the number of companies launching their first drug during the decade preceding 2018 more than tripled.
Cesare Ferrari
APRIL 27, 2024
In the medical device business, the capacity for innovation is commonly regarded as a key competence and a powerful response mechanism for companies operating in our complex and highly competitive environment. The purpose of this post is to help MedTech professionals to better understand the different types of innovation.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cesare Ferrari
NOVEMBER 6, 2022
The definitions by Geoffrey Moore are prevalent, and people in the healthcare business frequently refer to the concepts in his book Crossing the Chasm. In search of a better solution, they began to use manual instruments and surgical drills or competitive products. References. Crossing the Chasm. Oxford, UK: Capstone Publishing.
Clarify Health
OCTOBER 3, 2022
The Future of Healthcare’s Price Transparency is Here. Healthcare providers and insurers are now required to publicly disclose what they pay hospitals, doctors, and other medical providers. We’re in phase 1 of healthcare’s price transparency movement – internet data dump – but what’s next?
Clarify Health
OCTOBER 3, 2022
Recorded Session from the 2022 Consumer Experience & Digital Health Forum The Future of Healthcare’s Price Transparency is Here. Healthcare providers and insurers are now required to publicly disclose what they pay hospitals, doctors, and other medical providers. “I think the healthcare market is probably very similar.
PM360
APRIL 25, 2023
Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. The increase, from ASP plus 6% to ASP plus 8%, will last for five years, and may help increase access to and utilization of biosimilars and promote competition in the marketplace.
European Pharmaceutical Review
DECEMBER 21, 2022
The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero.
Expert insights. Personalized for you.
90 
Let's personalize your content